NCT02106858 2023-07-24
StivargaPMS
Bayer
Completed
Clinical Trials
10 trialsNCT02638766 2023-03-27
REGISTRI
Grupo Espanol de Investigacion en Sarcomas
Phase 2 Completed
NCT03465722 2022-10-06
(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST
Blueprint Medicines Corporation
Phase 3 Completed
NCT01933958 2022-04-01
Regorafenib Post-marketing Surveillance in Japan
Bayer
Completed
NCT02164240 2021-06-14
SURE
Dana-Farber Cancer Institute
Phase 1 Completed
NCT01271712 2021-01-29
GRID
Bayer
Phase 3 Completed
NCT01068769 2020-08-24
Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02889328 2020-01-09
Phase II Study of Regorafenib Continuous Dosing of Regorafenib in Patients With GISTs
Asan Medical Center
Phase 2 Completed
NCT02606097 2019-03-21
Regorafenib in GIST With Secondary C-KIT Exon 17 Mutation
Chang Gung Memorial Hospital
Phase 2 Completed
NCT02800330 2018-08-02
REGORA
Erasmus Medical Center
Phase 4 Completed